| Filing Date |
Description |
| 2012-12-21 |
Mr. Sutton,
48, has over 25 years of product development and manufacturing experience in the medical technology industry. Prior to joining the Company, Mr. Sutton served in increasingly senior positions at St. Jude Medical over the past ten years,
in ... |
| 2012-12-21 |
Mr. Sutton,
48, has over 25 years of product development and manufacturing experience in the medical technology industry. Prior to joining the Company, Mr. Sutton served in increasingly senior positions at St. Jude Medical over the past ten years,
in ... |
| 2012-12-12 |
(b) Russell C. Hirsch, M.D., Ph.D. resigned as a member of our Board of Directors
on December 10, 2012 and James M. Shapiro resigned as a member of our Board of Directors on December 11, 2012. ... |
| 2012-12-12 |
(b) Russell C. Hirsch, M.D., Ph.D. resigned as a member of our Board of Directors
on December 10, 2012 and James M. Shapiro resigned as a member of our Board of Directors on December 11, 2012. ... |
| 2012-10-31 |
Under the terms of the Amended License Agreement, the Company agreed to
expand the scope of the Company’s patent portfolio license to ISOI, which license remains limited to ISI’s Field of Use (as defined in the Original Agreement), to inclu ... |
| 2012-08-17 |
(b) On August 13, 2012, Michael T. MacKinnon, our Vice President of North American Sales Operations, resigned
from his employment with us, effective as of August 31, 2012, in order to become president of a privately-held, venture capital backed medic ... |
| 2012-07-25 |
(d) On July 25, 2012, the Board of Directors (the “Board”) of
Hansen Medical, Inc. increased the authorized size of the Board to nine members, creating two vacancies on the Board. ... |
| 2012-07-25 |
(d) On July 25, 2012, the Board of Directors (the “Board”) of
Hansen Medical, Inc. increased the authorized size of the Board to nine members, creating two vacancies on the Board. ... |
| 2012-06-04 |
On June 4, 2012, Hansen Medical, Inc. issued a press release announcing that it received 510(k) clearance from the U.S. Food and Drug Administration for its Magellan™ Robotic System for
peripheral vascular interventions. ... |
| 2012-06-01 |
2.
To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche, LLP as the Company’s independent registered public
accounting firm of the Company for its fiscal year ending December 31, 2012. The proposals ... |
